|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2005-6-16
|
|
pubmed:abstractText |
The main goals were to study the safety and tolerability of the alpha-emitter radium-223 (223Ra) in breast and prostate cancer patients with skeletal metastases. In addition, pain palliation was evaluated.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4451-9
|
|
pubmed:meshHeading |
pubmed-meshheading:15958630-Adult,
pubmed-meshheading:15958630-Aged,
pubmed-meshheading:15958630-Aged, 80 and over,
pubmed-meshheading:15958630-Alkaline Phosphatase,
pubmed-meshheading:15958630-Alpha Particles,
pubmed-meshheading:15958630-Bone Neoplasms,
pubmed-meshheading:15958630-Breast Neoplasms,
pubmed-meshheading:15958630-Diarrhea,
pubmed-meshheading:15958630-Dose-Response Relationship, Radiation,
pubmed-meshheading:15958630-Fatigue,
pubmed-meshheading:15958630-Female,
pubmed-meshheading:15958630-Follow-Up Studies,
pubmed-meshheading:15958630-Humans,
pubmed-meshheading:15958630-Injections, Intravenous,
pubmed-meshheading:15958630-Leukopenia,
pubmed-meshheading:15958630-Male,
pubmed-meshheading:15958630-Middle Aged,
pubmed-meshheading:15958630-Nausea,
pubmed-meshheading:15958630-Neutropenia,
pubmed-meshheading:15958630-Pain,
pubmed-meshheading:15958630-Prostatic Neoplasms,
pubmed-meshheading:15958630-Radium,
pubmed-meshheading:15958630-Treatment Outcome,
pubmed-meshheading:15958630-Vomiting
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases.
|
|
pubmed:affiliation |
Radiumhemmet, The Karolinska Hospital and Institute, Stockholm, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
